Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:AMSOTCMKTS:BRTXQNASDAQ:OPGNNASDAQ:PIII On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMSAmerican Shared Hospital Services$2.36$2.64$2.33▼$4.60$15.15M0.6643,764 shs3,452 shsBRTXQBioRestorative Therapies$1.78+0.9%$1.74$0.00▼$0.06$2.92B102.3662.17 million shs8,561 shsOPGNOpGen$4.70+4.4%$4.55$0.53▼$5.25$47.32M-1.719,941 shs14,220 shsPIIIP3 Health Partners$6.62+2.3%$8.28$6.47▼$33.73$47.59M0.8420,337 shs1,984 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMSAmerican Shared Hospital Services0.00%-2.07%-15.26%-11.94%-11.94%BRTXQBioRestorative Therapies+0.86%+1.72%+0.01%+14.85%+45.91%OPGNOpGen+4.44%0.00%-5.62%+374.80%+73.43%PIIIP3 Health Partners+2.32%-7.80%-23.20%-28.47%-77.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMSAmerican Shared Hospital ServicesN/AN/AN/AN/AN/AN/AN/AN/ABRTXQBioRestorative TherapiesN/AN/AN/AN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/APIIIP3 Health Partners1.2569 of 5 stars3.32.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMSAmerican Shared Hospital Services 0.00N/AN/AN/ABRTXQBioRestorative Therapies 0.00N/AN/AN/AOPGNOpGen 0.00N/AN/AN/APIIIP3 Health Partners 2.50Moderate Buy$16.25145.47% UpsideCurrent Analyst Ratings BreakdownLatest AMS, PIII, OPGN, and BRTXQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025PIIIP3 Health PartnersLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $20.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMSAmerican Shared Hospital Services$21.33M0.71$0.79 per share2.97$4.17 per share0.57BRTXQBioRestorative Therapies$110K26,533.62N/AN/A($0.68) per share-2.62OPGNOpGen$2.67M17.70N/AN/A($11.55) per share-0.41PIIIP3 Health Partners$1.49B0.03$2.85 per share2.32$0.45 per share14.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMSAmerican Shared Hospital Services$610K$0.603.937.87N/A15.74%4.01%2.11%8/12/2025 (Estimated)BRTXQBioRestorative Therapies-$12.52M-$1.07N/A∞N/AN/AN/AN/AN/AOPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)PIIIP3 Health Partners-$57.77M-$47.28N/AN/AN/A-6.95%-71.31%-11.93%8/6/2025 (Estimated)Latest AMS, PIII, OPGN, and BRTXQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PIIIP3 Health Partners-$5.00-$6.28-$1.28-$6.28$362.09 million$373.23 million3/27/2025Q4 2024PIIIP3 Health Partners-$8.50-$16.00-$7.50-$0.36$378.88 million$370.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMSAmerican Shared Hospital ServicesN/AN/AN/AN/AN/ABRTXQBioRestorative TherapiesN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/APIIIP3 Health PartnersN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMSAmerican Shared Hospital Services0.341.461.46BRTXQBioRestorative TherapiesN/AN/AN/AOPGNOpGenN/A5.455.45PIIIP3 Health Partners1.110.530.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMSAmerican Shared Hospital Services23.16%BRTXQBioRestorative TherapiesN/AOPGNOpGen2.68%PIIIP3 Health Partners7.75%Insider OwnershipCompanyInsider OwnershipAMSAmerican Shared Hospital Services23.00%BRTXQBioRestorative Therapies12.20%OPGNOpGen43.80%PIIIP3 Health Partners17.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMSAmerican Shared Hospital Services106.42 million4.94 millionNot OptionableBRTXQBioRestorative Therapies71.64 billionN/ANot OptionableOPGNOpGen10010.07 million4.70 millionNot OptionablePIIIP3 Health Partners5007.19 million294.74 millionNot OptionableAMS, PIII, OPGN, and BRTXQ HeadlinesRecent News About These CompaniesWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.June 6 at 11:54 AM | globenewswire.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.June 3, 2025 | globenewswire.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.May 27, 2025 | globenewswire.comDown 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in P3 Health Partners (PIII)May 26, 2025 | zacks.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.May 23, 2025 | globenewswire.comP3 Health Partners Inc. (NASDAQ:PIII) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comP3 Health Partners Inc (PIII) Q1 2025 Earnings Report Preview: What To Look ForMay 16, 2025 | finance.yahoo.comP3 Health Partners Inc (PIII) Q1 2025 Earnings Call Highlights: Strategic Adjustments and ...May 16, 2025 | finance.yahoo.comP3 Health Partners reaffirms $130M EBITDA improvement plan as operational initiatives accelerate in 2025May 16, 2025 | msn.comP3 Health Partners Inc. (PIII) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comP3 Health Partners Inc. (PIII) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2025 | zacks.comP3 Health Partners Announces First Quarter 2025 ResultsMay 15, 2025 | businesswire.comP3 Health Partners (NASDAQ:PIII) Stock Price Down 3% - Here's What HappenedMay 15, 2025 | marketbeat.comP3 Health Partners (PIII) to Release Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.comP3 Health Partners price target lowered to $20 from $50 at Lake StreetApril 21, 2025 | markets.businessinsider.comP3 Health Partners (PIII) Stock Jumps 8.9%: Will It Continue to Soar?April 16, 2025 | zacks.comP3 Health Partners Earnings Estimates, EPS & Revenue | NASDAQ:PIII | BenzingaApril 15, 2025 | benzinga.comP3 Health Partners Earnings Estimates, EPS & Revenue | NASDAQ:PIII | BenzingaApril 15, 2025 | benzinga.comP3 Health Partners Inc trading halted, news pendingApril 12, 2025 | markets.businessinsider.comP3 Health Partners to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | businesswire.comP3 Health Partners (PIII) Gets a Hold from TD CowenMarch 29, 2025 | markets.businessinsider.comMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsMicrosoft Could Rally as EU Antitrust Case Nears ResolutionBy Chris Markoch | May 21, 2025View Microsoft Could Rally as EU Antitrust Case Nears ResolutionWilliams-Sonoma: A Fundamentally Good Buy On Sale NowBy Thomas Hughes | May 23, 2025View Williams-Sonoma: A Fundamentally Good Buy On Sale NowWhy Investors Should Be Careful About AMC's Bitcoin DreamsBy Gabriel Osorio-Mazilli | May 8, 2025View Why Investors Should Be Careful About AMC's Bitcoin DreamsAMS, PIII, OPGN, and BRTXQ Company DescriptionsAmerican Shared Hospital Services NYSEAMERICAN:AMS$2.36 0.00 (0.00%) Closing price 06/6/2025 04:10 PM EasternExtended Trading$2.44 +0.08 (+3.22%) As of 06/6/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.American Shared Hospital Services provides stereotactic radiosurgery and advanced radiation therapy equipment. It operates in two segments, Medical Equipment Leasing, and Retail. The company offers radiosurgery equipment for the Gamma Knife stereotactic radiosurgery, a non-invasive procedure to treat malignant and benign brain tumors, and arteriovenous malformations, as well as for trigeminal neuralgia. It also provides financing services for Leksell Gamma Knife units; and leases medical equipment. In addition, the company offers proton beam radiation therapy services in Orlando, Florida and Long Beach, California, as well as offers planning, installation, reimbursement, and marketing support services to its customers. The company markets its solutions to cancer treatment centers, hospitals, and cancer networks worldwide. American Shared Hospital Services was founded in 1980 and is based in San Francisco, California.BioRestorative Therapies OTCMKTS:BRTXQ$1.78 +0.02 (+0.86%) As of 06/5/2025BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of New York.OpGen NASDAQ:OPGN$4.70 +0.20 (+4.44%) As of 06/6/2025 03:59 PM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.P3 Health Partners NASDAQ:PIII$6.62 +0.15 (+2.32%) Closing price 06/6/2025 03:57 PM EasternExtended Trading$6.63 +0.01 (+0.15%) As of 06/6/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
